Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Early invasive Strategy for Non-ST Elevation ACS in Chronic Kidney Disease

Many randomized studies and systematic revisions have shown that an early invasive approach (within 24hrs. after diagnosis) will not reduce mortality across the non-ST elevation acute coronary syndrome (NST-ACS) population, hence the relevance of NST-ACS; patients with a GRACE score higher than 140 were the ones showing improved outcomes. 

Estrategia invasiva temprana para síndromes coronarios agudos en enfermedad renal crónica

Roughly 40% of NST-ACS patients have chronic kidney disease (CKD) at varying stages. However, the latest guidelines of the European Society of Cardiology have yet to define a specific treatment for these patients. In some cases, postponing the coronary angiogram might be an opportunity to increase hydration and therefore improve prior preparation. 

The aim of this study was to find out the association between an early invasive strategy and mortality in a cohort of patient with CKD and NST-ACS

A retrospective study of all NST-ACS patients undergoing early invasive strategy at the Sheba Medical Center (Israel) was carried out. Primary end point was all cause mortality. 

Of 7107 NST-ACS patients, 50% was treated with an early approach (3259 patients). Mean age was 66±11, and 77% were men. 1837 patients (52%) received a coronary angiogram within 24 hours. 

Read also: Spontaneous Coronary Artery Dissection: Treatment and Prognosis.

Early invasive strategy patients were younger, had fewer comorbidities, better kidney function and higher troponin levels. They also had lower rate of multivessel/ left main disease (33% vs 40%; P<0.001).

At mean 4-year followup, 15% of these patients died and 30-day mortality was higher in patients with CKD in both groups. During followup, the lowest rates of kidney disease were associated with worse survival rate; patients with moderate to severe CKD had 66% more chances of dying, vs the population with mild or no CKD (CI 95% 1.3-2.1; P<0.001). Patients with severe CKD had 4 times more chances of dying (CI 95% 3.0-5.3; P <0.001).

After Inverse probability weighting treatment (IPWT), the early invasive strategy was associated to 30% lower mortality (CI 95% 0.56-0.85; P<0.001). This benefit was compromised by CKD, and there was no significant difference in patients with moderate to severe disease (glomerular filtration <44ml/min).

Conclusion

The association between early invasive strategy and long-term survival varies according to kidney function: the more dysfunctional (GF <44), the lower the benefit of an early intervention, as regards mortality. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Original Title: Early Invasive Strategy and Outcome of Non–ST-Segment Elevation Myocardial Infarction Patients With Chronic Kidney Disease.

Source: Sharon A, Massalha E, Fishman B, Fefer P, Barbash IM, Segev A, Matetzky S, Guetta V, Grossman E, Maor E. Early Invasive Strategy and Outcome of Non-ST-Segment Elevation Myocardial Infarction Patients With Chronic Kidney Disease. JACC Cardiovasc Interv. 2022 Oct 10;15(19):1977-1988. doi: 10.1016/j.jcin.2022.08.008. PMID: 36202565.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...